Procept Biorobotics

Procept Biorobotics Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Procept Biorobotics (PRCT) as of Nov 6, 2026 is 4.03. In the previous year, Net Debt to Free Cash Flow Ratio was 2.72 — a change of 47.81% (higher).

Net Debt/FCF

4.03

YoY

47.81%

Last updated:

Net Debt to Free Cash Flow Ratio of Procept Biorobotics is 2025 4.03 . Net Debt to Free Cash Flow Ratio of Procept Biorobotics was 2024 2.72 . It decreases by 47.81% higher compared to the previous year.

The Procept Biorobotics Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2019
0.37 USD
Jan 1, 2020
1.05 USD
Jan 1, 2021
4.39 USD
Jan 1, 2022
2.06 USD
Jan 1, 2023
1.55 USD
Jan 1, 2024
2.72 USD
Jan 1, 2025
4.03 USD
The Procept Biorobotics Net Debt/FCF history
YEARNet Debt/FCFYoY
4.03+47.81%
2.72+76.24%
1.55-25.14%
2.06-52.97%
4.39+317.11%
1.05+187.62%
0.37—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Procept Biorobotics Stock analysis

What does Procept Biorobotics do? PROCEPT BioRobotics Corp (PROCEPT) is a California-based medical technology company specializing in the development of robotic technologies for urological surgery. History: PROCEPT was founded in 2013 by Dr. Chin and his group at Johns Hopkins University School of Medicine. They developed a novel technology that had the potential to revolutionize the treatment of prostate cancer. PROCEPT used a robust Intuitive Surgical platform and developed a novel tissue classification technology that allows surgeons to operate with accuracy and safety. The first system, called AquaBeam®, was approved by the US Food and Drug Administration (FDA) in 2018 and has since been in use in Europe and the US. Business: PROCEPT aims to improve urological surgery through the use of robotic technologies, thereby increasing patient safety and care. The company focuses on the development and commercialization of robotic systems for the treatment of prostate cancer and other urological diseases. Products: PROCEPT has developed Aquablation®, a robotic system for the treatment of prostate cancer. It is a minimally invasive technology that uses high-precision waterjet cutting (accuracy reduced to millimeters) to remove cancerous tissue quickly, effectively, and accurately. The technology can also be used in surgical procedures on the bladder, urethra, and other urological organs. Divisions: PROCEPT has a broad portfolio of services and products in the field of urological surgery. The AquaBeam® technology is the first system developed to treat malignant prostate tumors using robotic technologies. The technology is used in hospitals, clinics, and medical facilities worldwide. In addition, PROCEPT offers training and support for surgeons and medical personnel. Conclusion: PROCEPT BioRobotics Corp is an emerging medical technology company specializing in robotics-based urological surgery. The AquaBeam® technology is an innovative, robotic technology for the treatment of prostate cancer. The company is on its way to revolutionizing urological surgery and making a significant contribution to improving healthcare. Procept Biorobotics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Procept Biorobotics stock

Net Debt to Free Cash Flow Ratio of Procept Biorobotics is 4.03 in 2025.

Net Debt to Free Cash Flow Ratio of Procept Biorobotics changed from 2.72 to 4.03, representing a 47.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Procept Biorobotics since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Procept Biorobotics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Procept Biorobotics

All Key Metrics — Procept Biorobotics